Biotech Startups

StemBond makes SENCE, a range of cell culture well plates (6 to 96 wells), coverslips and inserts pre-coated with a proprietary animal-free hydrogel tuned to tissue-relevant stiffnesses. The synthetic, xeno-free surfaces are sold as reorderable consumables to researchers and biotechs to reduce variability and improve reproducibility in standard cell culture workflows.

1 investor

StemInov is a biotech developing WhartSep, an off-the-shelf stem cell therapy derived from umbilical cord (Wharton's jelly) cells with three complementary actions to treat severe pneumonia and sepsis. The company targets immune disorders and tissue repair as unmet medical needs.

1 investor

Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer. It is part of the Menarini Group, an international pharmaceutical and diagnostics company.

1 investor

Stemmatters is a Contract Development and Manufacturing Organisation (CDMO) focused on regenerative medicine, providing product and process development plus cGMP production and clinical translation of medicinal products. It supports customers with CMC activities, regulatory dossier preparation, and clinical batch release for investigational and advanced therapy medicinal products.

1 investor

Stemnovate provides an integrated platform combining multiomics data, cell reprogramming technology, and mechanistic functional studies to accelerate drug discovery and clinical translation for rare diseases, neurodegenerative conditions, and other therapeutic areas across human and animal health. The company operates cellular biobanks, develops microphysiological systems for in vitro testing, and partners with pharmaceutical and academic institutions to reduce reliance on animal testing while enabling precision medicine research.

1 investor

Stem Pharm develops therapeutics using stem cell technology for disease treatment and drug discovery. The company serves pharmaceutical and biotech partners seeking advanced cell-based approaches to translational drug development.

1 investor

StemSight develops stem cell-based therapies to restore sight, focusing on treatments for corneal conditions such as limbal stem cell deficiency using pluripotent stem cells. The company, spun out of the Skottman Lab's Eye Regeneration Group, targets patients with untreatable eye diseases in collaboration with cornea clinicians.

1 investor

STENTiT is a Dutch medtech company developing the Resorbable Fibrillated Scaffold (RFS), a device designed to trigger natural healing and reconstruct arteries for treating vascular conditions. The technology initially targets below-the-knee chronic limb threatening ischemia and has broader applications across endovascular treatments.

1 investor

Sterilex develops sanitation, disinfection, and microbial control products for use in food processing facilities, water systems, and animal environments.

1 investor

Stiefel is a biopharmaceutical company that discovers, develops and delivers medicines and vaccines. Its R&D focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

1 investor

StimLabs develops regenerative medicine products, including its Corplex P device, used by physicians for wound healing and complex clinical cases. The company markets a portfolio of regenerative technologies for patient care.

1 investor

StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.

1 investor

1 investor

Stingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.

1 investor

Strand AI predicts missing biological data modalities from existing patient data, converting single histopathology slides into spatial protein maps and inferring gene expression from genotype. The platform serves researchers and clinicians in computational pathology and genomics.

1 investor

Strand Life Sciences enables precision medicine globally through bioinformatics, genomics analysis, and clinical research services. The company develops AI-driven platforms and analytical tools for omics data processing, including automated oncology panel reporting and digital histopathology infrastructure.

1 investor

Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors. The company targets patients with advanced solid tumors where current treatment options are limited.

1 investor

Stream Biomedical is a clinical-stage biotechnology company developing LG3, a biologic derived from a natural repair protein intended to protect and restore the brain by activating its repair systems. Its lead program targets Alzheimer's disease and related dementias, with potential use in stroke, traumatic brain injury, and other neurological conditions.

1 investor

Dennis Gong is a PhD candidate in Medical Engineering and Medical Physics at Harvard Medical School and MIT, conducting research on therapeutic resistance and recurrence in pancreatic cancer at MGH Center for Cancer Research and the Broad Institute. His stated goal is to build biotech companies and develop transformative new medicines.

1 investor

StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases. The company focuses on drug development and AAV manufacturing in the gene therapy field.

1 investor

Structura Biotechnology develops computational software and methods that scale cryo-EM structure determination for drug discovery and life sciences research. The company's platforms deliver high-resolution 3D protein reconstructions and real-time analysis for academic and pharmaceutical research teams.

1 investor

Stuart Therapeutics is a clinical-stage pharmaceutical company developing synthetic collagen mimetic peptides (its PolyCol platform) designed to bind and repair damaged helical collagen in the extracellular matrix. Its therapies target chronic eye diseases including dry eye disease, glaucoma, and inherited retinal disorders such as retinitis pigmentosa and age-related macular degeneration.

1 investor

Suanfarma develops, manufactures, and distributes active pharmaceutical ingredients (APIs) for the global pharmaceutical industry, serving over 400 customers across 70+ countries. The company operates as a B2B contract development and manufacturing organization (CDMO) providing end-to-end solutions for small-molecule drug substances and intermediates using fermentation and chemical synthesis.

1 investor

Succipro is a biotech spin-off from IRB CatSud and Universitat Rovira i Virgili developing first-in-class drugs that modulate succinate to treat inflammatory bowel disease and metabolic disorders. Its lead program targets inflammatory bowel disease, with additional planned indications in metabolic conditions such as metabolic dysfunction-associated fatty liver.

1 investor